Assessment of Adherence to Imatinib and Health-Related Quality of Life Among Patients with Gastrointestinal Stromal Tumor: A Cross-Sectional Study in an Oncology Clinic in Malaysia

References

• von Mehren M, Joensuu H. Gastrointestinal stromal tumors. J Clin Oncol. 2018;36(2):136–143. doi:10.1200/JCO.2017.74.9705
   PubMed Web of Science ®Google Scholar
• Le Cesne A, Ray-Coquard I, Bui BN, et al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol. 2010;11(10):942–949. doi:10.1016/S1470-2045(10)70222-9
   PubMed Web of Science ®Google Scholar
• Blay JY, Le Cesne A, Ray-Coquard I, et al. Prospective multicentric randomized Phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French sarcoma group. J Clin Oncol. 2007;25(9):1107–1113. doi:10.1200/JCO.2006.09.0183
   PubMed Web of Science ®Google Scholar
• World Health Organization. Adherence to Long-Term Therapies: evidence for Action; 2003. Available from: https://www.who.int/chp/knowledge/publications/adherence_full_report.pdf?ua=1. Accessed May 31, 2021.
   Google Scholar
• Noens L, Van Lierde MA, De Bock R, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009;113(22):5401–5411. doi:10.1182/blood-2008-12-196543
   PubMed Web of Science ®Google Scholar
• Geissler J, Sharf G, Bombaci F, et al. Factors influencing adherence in CML and ways to improvement: results of a patient-driven survey of 2546 patients in 63 countries. J Cancer Res Clin Oncol. 2017;143(7):1167–1176. doi:10.1007/s00432-017-2372-z
   PubMed Web of Science ®Google Scholar
• Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28(14):2381–2388. doi:10.1200/JCO.2009.26.3087
   PubMed Web of Science ®Google Scholar
• Unnikrishnan R, Veeraiah S, Mani S, et al. Comprehensive evaluation of adherence to therapy, its associations, and its implications in patients with chronic myeloid leukemia receiving imatinib. Clin Lymphoma Myeloma Leuk. 2016;16(6):366–371. doi:10.1016/j.clml.2016.02.040
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang P, Han Y, et al. Adherence to adjuvant imatinib therapy in patients with gastrointestinal stromal tumor in clinical practice: a Cross-Sectional Study. Chemotherapy. 2019;64(4):197–204. doi:10.1159/000505177
   PubMed Web of Science ®Google Scholar
• Tsang J, Rudychev I, Pescatore SL. Prescription compliance and persistency in chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST) patients (pts) on imatinib (IM) [abstract]. J Clin Oncol. 2006;24(18 suppl):6119. doi:10.1200/jco.2006.24.18_suppl.6119
   Web of Science ®Google Scholar
• Mazzeo F, Duck L, Joosens E, et al. Nonadherence to imatinib treatment in patients with gastrointestinal stromal tumors: the ADAGIO study. Anticancer Res. 2011;31(4):1407–1409.
   Web of Science ®Google Scholar
• Feng W, Henk H, Thomas S, et al. Compliance and persistency with imatinib [abstract]. J Clin Oncol. 2006;24(18 suppl):6038. doi:10.1200/jco.2006.24.18_suppl.6038
   Web of Science ®Google Scholar
• Lee PM, Chang CT, Yusoff ZM. Adherence to tyrosine kinase inhibitors among adult chronic myeloid leukemia patients in a Malaysia hospital. Int J Clin Pharm. 2021;43(1):46–54. doi:10.1007/s11096-020-01070-9
   Web of Science ®Google Scholar
• Tan BK, Tan SB, Chen LC, et al. Medication-related issues associated with adherence to long-term tyrosine kinase inhibitors for controlling chronic myeloid leukemia: a qualitative study. Patient Prefer Adherence. 2017;11:1027–1034. doi:10.2147/PPA.S132894
   PubMed Web of Science ®Google Scholar
• Ministry of Health Malaysia. National Strategic Plan for Cancer Control Programme 2016–2020. 1st ed; 2017. Available from: https://www.moh.gov.my/index.php/dl/554756755a584a6961585268626938794d4445334c314a31616e567259573476546d46306157397559577866553352795958526c5a326c6a5831427359573566516d39766131396d61573568624541794e564e46554651794d4445334c6e426b5a673d3d. Accessed May 31, 2021.
   Google Scholar
• Daniel WW, Cross CL. Biostatistics: A Foundation for Analysis in the Health Sciences. 10th ed. New York: John Wiley & Sons; 2013.
   Google Scholar
• Hassan NB, Hasanah CI, Foong K, et al. Identification of psychosocial factors of noncompliance in hypertensive patients. J Hum Hypertens. 2006;20(1):23–29. doi:10.1038/sj.jhh.1001930
   Web of Science ®Google Scholar
• Zahrina AK, Norsa’adah B, Hassan NB, et al. Adherence to capecitabine treatment and contributing factors among cancer patients in Malaysia. Asian Pac J Cancer Prev. 2014;15(21):9225–9232. doi:10.7314/APJCP.2014.15.21.9225
   Google Scholar
• Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin. 2009;59(1):56–66. doi:10.3322/caac.20004
   PubMed Web of Science ®Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organisation for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–376. doi:10.1093/jnci/85.5.365
   PubMed Web of Science ®Google Scholar
• Yusoff N, Low W, Ch Y. The Malay version of the European Organization for research and treatment of cancer quality of life questionnaire (EORTC-QLQ C30): Reliability and Validity Study. Int Med J Malays. 2010;9(2):45–50.
   Google Scholar
• Efficace F, Baccarani M, Rosti G, et al. Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study. Br J Cancer. 2012;107(6):904–909. doi:10.1038/bjc.2012.348
   PubMed Web of Science ®Google Scholar
• Blay JY, Rutkowski P. Adherence to imatinib therapy in patients with gastrointestinal stromal tumors. Cancer Treat Rev. 2014;40(2):242–247. doi:10.1016/j.ctrv.2013.07.005
   PubMed Web of Science ®Google Scholar
• Anderson KR, Chambers CR, Lam N, et al. Medication adherence among adults prescribed imatinib, dasatinib, or nilotinib for the treatment of chronic myeloid leukemia. J Oncol Pharm Pract. 2015;21(1):19–25. doi:10.1177/1078155213520261
   PubMed Web of Science ®Google Scholar
• Verbrugghe M, Verhaeghe S, Lauwaert K, Beeckman D, Van Hecke A. Determinants and associated factors influencing medication adherence and persistence to oral anticancer drugs: a systematic review. Cancer Treat Rev. 2013;39(6):610–621. doi:10.1016/j.ctrv.2012.12.014
   PubMed Web of Science ®Google Scholar
• Fentie AM, Tadesse F, Engidawork E, Gebremedhin A. Prevalence and determinants of non-adherence to imatinib in the first 3-months treatment among newly diagnosed Ethiopian’s with chronic myeloid leukemia. PLoS One. 2019;14(3):e0213557. doi:10.1371/journal.pone.0213557
   Web of Science ®Google Scholar
• Chen LC, Chen TC, Huang Y-B, Chang CS. Disease acceptance and adherence to imatinib in Taiwanese chronic myeloid leukaemia outpatients. Int J Clin Pharm. 2014;36(1):120–127. doi:10.1007/s11096-013-9867-8
   PubMed Web of Science ®Google Scholar
• Eliasson L, Clifford S, Barber N, Marin D. Exploring chronic myeloid leukemia patients’ reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk Res. 2011;35(5):626–630. doi:10.1016/j.leukres.2010.10.017
   PubMed Web of Science ®Google Scholar
• Efficace F, Rosti G, Cottone F, et al. Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors. Leuk Res. 2014;38(3):294–298. doi:10.1016/j.leukres.2013.07.003
   PubMed Web of Science ®Google Scholar
• Joensuu H, Trent JC, Reichardt P. Practical management of tyrosine kinase inhibitor-associated side effects in GIST. Cancer Treat Rev. 2011;37(1):75–88. doi:10.1016/j.ctrv.2010.04.008
   Web of Science ®Google Scholar
• Dusetzina SB, Winn AN, Abel GA, Huskamp HA, Keating NL. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol. 2014;32(4):306–311. doi:10.1200/JCO.2013.52.9123
   PubMed Web of Science ®Google Scholar
• Streeter SB, Schwartzberg L, Husain N, Johnsrud M. Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions. J Oncol Pract. 2011;7(3 Suppl):46s–51s. doi:10.1200/JOP.2011.000316
   Google Scholar
• Lim YM, Eng WL, Chan HK. Understanding and challenges in taking tyrosine kinase inhibitors among Malaysian chronic myeloid leukemia patients: a qualitative study. Asian Pac J Cancer Prev. 2017;18(7):1925–1930.
   Google Scholar
• Sitlinger A, Zafar SY. Health-related quality of life: the impact on morbidity and mortality. Surg Oncol Clin N Am. 2018;27(4):675–684. doi:10.1016/j.soc.2018.05.008
   PubMed Web of Science ®Google Scholar